The Nu.Q canine cancer screening test, a diagnostic product manufactured by Volition, is now available through Idexx’s U.S. reference laboratory network.
Nu.Q uses a blood sample to detect 76% of systemic veterinary cancers with 97% specificity, according to a peer-reviewed case series performed by Texas A&M University researchers. Among the detected cancers are lymphoma, hemangiosarcoma and histiocytic sarcoma.
Idexx is well-positioned to roll out the test worldwide, said Tom Butera, DVM, the CEO of Volition Veterinary Diagnostics Development LLC.
“Our Nucleosomics technology is easy to incorporate into annual wellness visits to support veterinarians in their clinical decision-making, enable earlier detection and treatment of cancer, and improve the health and well-being of pets and pet owners,” Dr. Butera said.
Many dogs are diagnosed with cancer only after they become ill. Idexx hopes to change that fact by recommending a cancer screening test at annual wellness exams for all dogs older than 7 and for dogs ages 4 or older that are at an increased risk.
“Idexx’s launch of the Nu.Q canine cancer screen in the U.S., under our previously announced supply agreement, ultimately provides worldwide customer reach through its global reference laboratory network,” Dr. Butera said.
The Nu.Q canine test also is available for preorder on Heska’s point-of-care Element i+ immunodiagnostic analyzer.